You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Pathologies and the Use of Cerebrospinal-Fluid-Based Biomarkers in Alzheimer Disease

  1. What biomarkers are currently FDA approved for the diagnosis of AD?
    Aβ40 and neurofilament light
    Aβ42/40 and Aβ42/tau
    Tau and neurofilament light
    Neurofilament light
  2. Which APOE variant is associated with AD?
  3. Biomarkers for AD are judged by their concordance to what?
    Plasma markers
    Magnetic resonance imaging (MRI)
    Amyloid positron emission tomography (PET)
    Clinical diagnosis
  4. Which biomarkers for AD have been found to be different between racial groups?
    Aβ42, Aβ40, tau, neurofilament light
    Aβ40, tau, neurofilament light
    Tau and neurofilament light only
    Neurofilament light only
  5. Why are AD CSF biomarkers often used in a ratio?
    To negate individual differences
    To account for racial disparities
    To identify other neurological diseases
    Ratios are no more useful than individual markers alone